Reliability and validity of Fall Efficacy Scale-International in people with Parkinson’s disease during On- and Off-drug phases

Background and Aim : Since fear of falling may be one of the main problems in people with Parkinson’s disease (PD), its assessment with valid tools is necessary in both drug phases. This study was carried out to investigate the psychometric attributes of the Fall Efficacy Scale-International (FES-I) in people with PD, both in On and Off phases.Methods : One hundred twenty-four patients with PD (mean age±standard deviation, 60.33±12.59 years) were assessed with the FES-I, both in On- and Off-drug phases. Dimensionality, internal consistency, and test-retest reliability were respectively explored by means of factor analysis, Cronbach’s alpha, and Intraclass Correlation Coefficient. Convergent validity of FES-I was established with Visual Analog Scale-Fear of Falling, Berg Balance Scale, Functional Reach Test. Parkinson’s Disease Questionnaire-39 and Unified Parkinson Disease Rating Scale-Activities of Daily Living were also applied. Discriminative validity was tested between patients with and without a history of falling.Results : Factor analysis showed two factors for On- and one factor for Off-drug phase. Internal consistency (α=0.96, On phase; 0.98, Off phase) and test-retest reliability (0.94; 0.91) were satisfactory in both drug phases. A moderate/high correlation (rS=|0.50-0.70|) between FES-I and Visual Analog Scale-Fear of Falling, Berg Balance Scale, Functional Reach Test. Parkinson’s Disease Questionnaire-39 and Unified Parkinson Disease Rating Scale-Activities of Daily Living was achieved in both drug phases too. The sensitivity of FES-I to discriminate Parkinson’s disease with and without falls showed moderate effect size in both phases.Conclusion : This study verified that FES-I is unidimensional, reliable and valid to measure the Fear of Falling during On- and Off- drug phases in people with PD.

Keywords:

Fall Efficacy Scale-International , Parkinson’s disease , On- and Off- drug phases